ERYP Erytech Pharma S.A.

7.15
+0.14  (+2%)
Previous Close 7.01
Open 7.15
Price To Book 0.98
Market Cap 128,316,157
Shares 17,937,535
Volume 399
Short Ratio
Av. Daily Volume 3,848
Stock charts supplied by TradingView

NewsSee all news

  1. ERYTECH Announces a Poster Presentation for TRYbeCA1 at the ASCO 2020

    Greater than 50% enrollment achieved in ongoing Phase 3 trial of eryaspase in pancreatic cancer Trial in Progress Poster selected for inclusion in Poster Walk LYON, France and CAMBRIDGE, Mass., Jan. 24, 2020

  2. Monthly information related to total number of voting rights and shares composing the share capital – December 31, 2019

    LYON, France, Jan. 10, 2020 (GLOBE NEWSWIRE) -- Listing markets: Euronext Paris from Euronext (Market segment C -  ISIN Code: FR0011471135- Symbol: ERYP) & Nasdaq Global Select Market in the United-States

  3. Monthly information related to total number of voting rights and shares composing the share capital – November 30, 2019

    LYON, France, Dec. 02, 2019 (GLOBE NEWSWIRE) -- Listing markets: Euronext Paris from Euronext (Market segment C -  ISIN Code: FR0011471135- Symbol: ERYP) & Nasdaq Global Select Market in the United-States

  4. ERYTECH Announces Publication of its Phase 2b Trial of Eryaspase in Metastatic Pancreatic Cancer in the European Journal of Cancer

    LYON, France and CAMBRIDGE, Mass., Nov. 25, 2019 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Nasdaq and Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic

  5. ERYTECH Provides Business Update and Reports Financial Results for the Third Quarter of 2019

    TRYbeCA1, Phase 3 trial of eryaspase in second line pancreatic cancer: positive safety review by independent data monitoring committeeopened for patient enrollment in the United States first U.S. clinical sites

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2 trial completed.
Hydro-Lido
Hemorrhoids
Phase 3 trial to continue as planned following IDMC review.
Eryaspase (GRASPA)
Pancreatic cancer
Phase 2 data due 1H 2020.
Eryaspase (GRASPA)
Acute lymphoblastic leukemia (ALL) - front line
Phase 2 interim analysis due 3Q 2020.
Eryaspase (GRASPA) - TRYbeCA2
Triple-Negative Breast Cancer (TNBC)

Latest News

  1. ERYTECH Announces a Poster Presentation for TRYbeCA1 at the ASCO 2020

    Greater than 50% enrollment achieved in ongoing Phase 3 trial of eryaspase in pancreatic cancer Trial in Progress Poster selected for inclusion in Poster Walk LYON, France and CAMBRIDGE, Mass., Jan. 24, 2020

  2. Monthly information related to total number of voting rights and shares composing the share capital – December 31, 2019

    LYON, France, Jan. 10, 2020 (GLOBE NEWSWIRE) -- Listing markets: Euronext Paris from Euronext (Market segment C -  ISIN Code: FR0011471135- Symbol: ERYP) & Nasdaq Global Select Market in the United-States

  3. Monthly information related to total number of voting rights and shares composing the share capital – November 30, 2019

    LYON, France, Dec. 02, 2019 (GLOBE NEWSWIRE) -- Listing markets: Euronext Paris from Euronext (Market segment C -  ISIN Code: FR0011471135- Symbol: ERYP) & Nasdaq Global Select Market in the United-States

  4. ERYTECH Announces Publication of its Phase 2b Trial of Eryaspase in Metastatic Pancreatic Cancer in the European Journal of Cancer

    LYON, France and CAMBRIDGE, Mass., Nov. 25, 2019 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Nasdaq and Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic

  5. ERYTECH Provides Business Update and Reports Financial Results for the Third Quarter of 2019

    TRYbeCA1, Phase 3 trial of eryaspase in second line pancreatic cancer: positive safety review by independent data monitoring committeeopened for patient enrollment in the United States first U.S. clinical sites

  6. ERYTECH to Host Third Quarter 2019 Conference Call and Business Update on November 8, 2019

    LYON, France, Nov. 05, 2019 (GLOBE NEWSWIRE) -- ERYTECH Pharma (NASDAQ:ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood

  7. Monthly information related to total number of voting rights and shares composing the share capital – October 31, 2019

    LYON, France, Nov. 05, 2019 (GLOBE NEWSWIRE) -- Listing markets: Euronext Paris from Euronext (Market segment C -  ISIN Code: FR0011471135- Symbol: ERYP) & Nasdaq Global Select Market in the United-States

  8. ERYTECH Achieves Milestones in TRYbeCA1 Phase 3 Trial of Eryaspase in Second-line Pancreatic Cancer

    Trial opened for patient enrollment in the United States Independent Data Monitoring Committee recommends continuation of the trial as planned LYON, France and CAMBRIDGE, Mass., Nov. 04, 2019 (GLOBE NEWSWIRE) --

  9. Monthly information related to total number of voting rights and shares composing the share capital – September 30, 2019

    LYON, France, Oct. 04, 2019 (GLOBE NEWSWIRE) -- Listing markets: Euronext Paris from Euronext (Market segment C -  ISIN Code: FR0011471135- Symbol: ERYP) & Nasdaq Global Select Market in the United-States (Symbol

  10. ERYTECH Provides Business Update and Reports Financial Results for the First Half of 2019

    Conference call and webcast on Wednesday, September 18at 2:30 pm CET/8:30 am EDT TRYbeCA1, Phase 3 trial for eryaspase in second line pancreatic cancer, progressing on planImmune modulation collaboration entered into

  11. ERYTECH to Host Second Quarter 2019 Conference Call and Business Update

    LYON, France, Sept. 11, 2019 (GLOBE NEWSWIRE) -- ERYTECH Pharma (NASDAQ:ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood

  12. Monthly information related to total number of voting rights and shares composing the share capital – August 31, 2019

    LYON, France, Sept. 03, 2019 (GLOBE NEWSWIRE) -- Listing markets: Euronext Paris from Euronext (Market segment C -  ISIN Code: FR0011471135- Symbol: ERYP) & Nasdaq Global Select Market in the United-States